Rasagiline ratiopharm (rasagiline)
- Region
- 🇪🇺 EU
- Active substance
- rasagiline
- Company
- Teva B.V.
- Status
- Authorised
- Therapeutic area
- Parkinson Disease
- CHMP opinion
- Thu 20 Nov 2014
- EU approval
- Mon 12 Jan 2015
- Application
- EMEA/H/C/003957
- ATC
- N04BD02
- Official record
- www.ema.europa.eu
Indication
Rasagiline ratiopharm is indicated for the treatment of idiopathic Parkinson’s disease (PD) as monotherapy (without levodopa) or as adjunct therapy (with levodopa) in patients with end of dose fluctuations.
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 Rasagiline Viatris (previously Rasagiline Mylan) Authorised · Viatris Limited
- 🇪🇺 Azilect Authorised · Teva B.V.
Follow Rasagiline ratiopharm
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.